Skip to content
Verquvo(vericiguat)
Verquvo (vericiguat) is a small molecule pharmaceutical. Vericiguat was first approved as Verquvo on 2021-01-19. It has been approved in Europe to treat heart failure.
Download report
Favorite
FDA Novel Drug Approvals 2021
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
cardiovascular diseasesD002318
Trade Name
FDA
EMA
Verquvo
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Vericiguat
Tradename
Company
Number
Date
Products
VERQUVOMerck Sharp & DohmeN-214377 RX2021-01-19
3 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
verquvoNew Drug Application2021-01-19
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration
Code
VERICIGUAT, VERQUVO, MERCK SHARP DOHME
2026-01-19NCE
Patent Expiration
Patent
Expires
Flag
FDA Information
Vericiguat, Verquvo, Merck Sharp Dohme
96049482032-11-26DS, DPU-3062
84206562031-05-19DS, DP
89213772031-05-19U-3062
99934762031-05-19U-3062
107368962031-05-19DS, DP
114396422031-05-19U-3062
ATC Codes
C: Cardiovascular system drugs
— C01: Cardiac therapy drugs
— C01D: Vasodilators used in cardiac diseases
— C01DX: Other vasodilators used in cardiac diseases in atc
— C01DX22: Vericiguat
HCPCS
No data
Clinical
Clinical Trials
23 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Heart failureD006333EFO_0003144I503433113
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Left ventricular dysfunctionD018487—11——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Metabolic syndromeD024821EFO_0000195E88.81—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Coronary artery diseaseD003324I25.13————3
PharmacokineticsD0105991————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameVERICIGUAT
INNvericiguat
Description
Vericiguat is a pyrazolopyridine that is 5-fluoro-1H-pyrazolo[3,4-b]pyridine in which the amino hydrogen at position 1 has been substituted by a 2-fluorobenzyl group and the hydrogen at position 3 has been substituted by a 4,6-diamino-5-[(methoxycarbonyl)amino]pyrimidin-2-yl group. It is a soluble guanylate cyclase stimulator which is used for treatment of chronic heart failure. It has a role as a soluble guanylate cyclase activator, a vasodilator agent and an antihypertensive agent. It is an aminopyrimidine, a pyrazolopyridine, a carbamate ester and an organofluorine compound.
Classification
Small molecule
Drug classguanaline cyclase activators
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
COC(=O)Nc1c(N)nc(-c2nn(Cc3ccccc3F)c3ncc(F)cc23)nc1N
Identifiers
PDB—
CAS-ID1350653-20-1
RxCUI—
ChEMBL IDCHEMBL4066936
ChEBI ID—
PubChem CID54674461
DrugBankDB15456
UNII IDLV66ADM269 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 571 documents
View more details
Safety
Black-box Warning
Black-box warning for: Verquvo
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
20,983 adverse events reported
View more details